mTOR Inhibitors at a Glance.

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Mechanistic target of rapamycin (mTOR) is a serine/threonine kinase regulating cell growth and proliferation.
• mTOR is a validated therapeutic target for cancers driven by uncontrolled cell proliferation.
• The immunosuppressive drug rapamycin was the first identified mTOR inhibitor.

Purpose of the Study:

• To provide a concise summary of mTOR inhibitors.
• To highlight the development and clinical trial status of mTOR inhibitors for cancer treatment.

Main Methods:

• Literature review of mTOR inhibitors.
• Analysis of clinical trial data for mTOR inhibitors.

Main Results:

• Numerous mTOR inhibitors have been developed over the past decade.
• Many mTOR inhibitors are currently undergoing clinical trials for various cancers.

Conclusions:

• mTOR inhibitors represent a promising class of targeted cancer therapies.
• Further research and clinical evaluation are ongoing for mTOR-targeted treatments.